Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Clinical trial NCT05503667 · RECRUITING

Trial details

NCT number: NCT05503667
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Adenocarcinoma Stage III Lung Adenocarcinoma Stage IV EGFR Gene Mutation

Start date: 2022-02-01
Primary completion: 2023-10-01
Enrollment: 96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.